

13 November 2025

ASX Announcement

Webinar: FDA response to Galidesivir clinical development and approval pathway

MELBOURNE Australia, 13 November 2025: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise it will be hosting a webinar at 10:30am AEDT (7:30am AWST) on Monday, 17 November 2025.

During the webinar, CEO and Managing Director, Dr David Foster and Non-Executive Chairman, Mr Jason Carroll will provide an overview of the US Food & Drug Administration's (FDA) response to questions posed in a Type C Meeting Request regarding the use of the FDA's Animal Rule for Galidesivir's development and approval, as well as Galidesivir's eligibility for a Priority Review Voucher (PRV) and pending clinical development initiatives, including a proposed animal study in Marburg.

The briefing will be followed by a Q&A session. Questions can be submitted to henry.jordan@sdir.com.au prior, or in written form during the webinar. Anyone wishing to attend the webinar must register via the following:

- https://us02web.zoom.us/webinar/register/WN_pHTZX_7aQxKPUIVC2zIFHw#/registration
- **Date and time:** 10:30am AEDT (7:30am AWST) on Monday, 17 November 2025

A recording of the presentation will be made available following the initiative.

- Ends -

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.



ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.